Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kliniske resultater af USCTR vs. mOCTR

9. oktober 2026 opdateret af: Walter Reed National Military Medical Center

Kliniske resultater af karpaltunnelfrigivelse med og uden ultralydsvejledning

Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy and affects 3-6% of adults in the United States. In patients with severe or refractory symptoms, carpal tunnel release (CTR) represents the definitive management option, and over 550,000 CTRs are performed annually in the United States with over 90% of patients reporting clinical improvement. Currently available CTR techniques include mini-open CTR via a single, 1-3 cm palmar incision (mOCTR), endoscopic CTR via one (wrist) or two (wrist and palm) 1-2 cm incisions (ECTR), and ultrasound guided CTR via a single < 1 cm wrist or palmar incision (USCTR or CTR-US). The primary objective is to assess the impact of USCTR vs mOCTR in a military population. Investigators hypothesize that USCTR using the SX-One MicroKnife, also known as UltraGuideCTR, will safely and non-inferiorly improve symptoms of carpal tunnel syndrome compared to traditional mOCTR, without greater less loss of military duty days. This study is a single-site randomized controlled trial.

Participants with CTS will be randomized to a study arm and receive treatment with USCTR vs. traditional mOCTR. All patients will be followed for a period of 24 months with respect to standard clinical data, military relevant data, and validated patient related outcome measures (PROMs). Data will be collected at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, and 12 months, and 24 months post-CTR procedure, with the primary focus being on outcomes up to 1 year.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Clinical outcomes of up to 83 participants (updated target sample size) treated with USCTR vs. traditional mOCTR will be investigated.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

71

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20814
        • Walter Reed National Military Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 89 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults age ≥18 years
  • DEERS Eligible
  • Fluent in speaking, reading, and understanding English
  • Clinical diagnosis of Carpal Tunnel Syndrome (CTS)
  • Candidate for surgical CTR based on severe and/or refractory symptoms
  • Confirmatory electrodiagnostic test indicating median neuropathy at the wrist (abnormal findings)
  • Ultrasound findings consistent with median nerve enlargement in the carpal tunnel

Exclusion Criteria:

  • Previous carpal tunnel release or previous wrist surgery on the ipsilateral side
  • Carpal tunnel injection with corticosteroid within 6 weeks prior to anticipated study procedure
  • Previous traumatic injury to the median nerve or any of its branches on the ipsilateral side
  • History of medical condition that would preclude safe participation in study procedures (e. g. complex regional pain syndrome (CRPS), upper limb vascular disease (including thoracic outlet syndrome), Raynaud's phenomenon, etc.)
  • Inability to stop anticoagulation medications (Plavix, Coumadin/Warfarin, Xarelto), or unable to be bridged with Lovenox
  • Unable to understand and provide written informed consent
  • Contraindication to proceeding with USCTR based on diagnostic ultrasound (i.e. identification of anomalous anatomic structures such as transligamentous thenar motor branch or space occupying lesions within the carpal tunnel)
  • Electrodiagnostic evaluation of the carpal tunnel which indicates normal findings

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: USCTR Procedure

Participants will undergo the USCTR procedure with SX-One MicroKnife®, also known as UltraGuideCTR

Ultrasound guided CTR via a single < 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR

Aktiv komparator: mOCTR Procedure

Participants will undergo the traditional mOCTR procedure.

Mini-open CTR via a single 1-3cm palmar incision

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measure the Effect of USCTR vs mOCTR on the Longitudinal Change in QuickDASH.
Tidsramme: Change from baseline to 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. Change from baseline to 1 month, 1 year and 2 years were reported.

QuickDash is a region-specific PROM consisting of 11 items measuring the difficulty in performing physical activities relevant to shoulder, arm or hand function. Each item is scored on a scale of 1-5 and a final score of 0 to 100 is calculated, with higher scores representing greater degrees of upper extremity disability (0 points indicate no disability and 100 points indicates maximum disability).

For the primary analysis, change in QuickDASH score will be tracked across the first five occasions of assessment (i.e. baseline - 1 month) and the patient-level average trend will be compared between randomized groups. As a secondary analysis, change in QuickDASH will be tracked over the full duration of follow-up, with the primary focus being on outcomes up to 1 year.

Change from baseline to 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. Change from baseline to 1 month, 1 year and 2 years were reported.
Measure the Effect of USCTR vs mOCTR on the Longitudinal Change in BCTQ-SSS.
Tidsramme: Change from baseline to 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. Change from baseline to 1 month, 1 year and 2 years were reported.

The BCTQ is a PROM for CTS and is the most commonly used outcome measure for CTS. Each item on the 11-item symptom severity scale (BCTQ-SSS) is graded from 1 (mildest) to 5 (most severe). Outcomes are typically recorded as a mean score.

For the primary analysis, change in BCTQ-SSS score will be tracked across the first five occasions of assessment (i.e. baseline - 1 month) and the patient-level average trend will be compared between randomized groups. As a secondary analysis, change in BCTQ-SSS will be tracked over the full duration of follow-up, with the primary focus being on outcomes up to 1 year.

Change from baseline to 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. Change from baseline to 1 month, 1 year and 2 years were reported.
Measure the Effect of USCTR vs mOCTR on the Longitudinal Change in Hand Grip Strength.
Tidsramme: Change from baseline to 3 months, and 12 months post CTR procedure. Mean grip strength at baseline, 3 months and 12 months were reported.

Manually tested using a handheld dynamometer.

Between the mOCTR and USCTR groups, will compare hand grip strength across each time point (i.e. baseline - 3 months; baseline - 12 months).

Change from baseline to 3 months, and 12 months post CTR procedure. Mean grip strength at baseline, 3 months and 12 months were reported.
Measure the Effect of USCTR vs mOCTR on the Longitudinal Change in Pinch (Tip, Palmar, and Key) Strength.
Tidsramme: Change from baseline to 3 months, and 12 months post CTR procedure. Mean pinch (tip, palmar, and key) strength at baseline, 3 months and 12 months were reported.

Manually tested using a pinch gauge.

Between the mOCTR and USCTR groups, will compare pinch (tip, palmar, and key) strength across each time point (i.e. baseline - 3 months; baseline - 12 months).

Change from baseline to 3 months, and 12 months post CTR procedure. Mean pinch (tip, palmar, and key) strength at baseline, 3 months and 12 months were reported.
Measure the Impact of USCTR vs mOCTR on Participant Perception of Change in Overall Physical Condition
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. % of participants that reported a GROC score of ≥ 5/7 at 1 month, 1 year, and 2 years were reported.

Participant self reported change in physical condition. Participant will select one response from the following descriptions to rate overall condition from the time they began treatment to the designated time-point: A very great deal worse; About the same; A very great deal better; A great deal worse; A great deal better; Quite a bit worse; Quite a bit better; Moderately worse; Moderately better; Somewhat worse; Somewhat better; A little bit worse; A little bit better; A tiny bit worse(almost the same); A tiny bit better (almost the same)

The Global Rate of Change Scale (GROC) will be captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post-CTR. The primary focus will be on outcomes up to 1 year.

Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure were assessed. % of participants that reported a GROC score of ≥ 5/7 at 1 month, 1 year, and 2 years were reported.
Change in Military Work Status as Assessed Using Single-item Self-report Assessment
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. Status at 1 month, 1 year and 2 years were reported.

Participants will complete a questionnaire to depict when normal work or daily activities commenced.

The primary focus will be on outcomes up to 1 year.

Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. Status at 1 month, 1 year and 2 years were reported.
Surgical Time During Procedure (Minutes)
Tidsramme: Recorded at end of procedure (Baseline)

On the day the participant receives their study assigned procedure (USCTR vs. mOCTR), clinical team will record surgical time to perform the procedure in minutes. Surgical time was defined as the time from initial cut to incision closure.

Recorded at end of procedure (Baseline)
Change in Self-reported Satisfaction as Assessed Using a Satisfaction Rating Scale
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. % of participants that reported a score of ≥ 5/7 at 1 month, 1 year and 2 years were reported.

Participants will rate satisfaction with the following: completely dissatisfied, mostly dissatisfied, somewhat satisfied, neither satisfied or dissatisfied, somewhat satisfied, mostly satisfied, or completely satisfied.

Completely dissatisfied with represent the lowest score, and completely satisfied will represent the highest score.

Will compare participant satisfaction across arms in terms of symptom improvement, incision appearance, and recovery, with the primary focus being on outcomes up to 1 year.

Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. % of participants that reported a score of ≥ 5/7 at 1 month, 1 year and 2 years were reported.
Change in Self-reported Pain as Assessed Using the 11-item Numeric Pain Rating Scale (NPRS) Participant Pain Levels Over 1 Month Following the CTR Procedure.
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, and 1 month post CTR procedure. Change from baseline to 1 month was reported.

The 11-item NPRS scale is a unidimensional measure of pain intensity. It is a segmented numeric version of the visual analog scale in which participants will select a whole number (0-10 integers) that best reflects the intensity of their pain. The scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. worst possible pain).

Captured at 1 week, 2 weeks, 3 weeks, and 1 month post CTR procedure. Change from baseline to 1 month was reported.
Change in Pain Medication Usage as Assessed Using Single-item Self-report Assessment
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. Mean opioid use frequency at baseline and 1 week were reported due to highest clinical relevance.

Participant self-reported pain medication usage. Pain medication use frequency was self-reported on a scale from 0-5. The following frequency of use options are as follows: 0 = No use, 1 = Less than once a week, 2 = Once a week, 3 = Several times a week, 4 = Daily, 5 = Multiple times per day.

Participant self-reported pain medication usage (e.g., cumulative dosage, drug category, duration of use, etc.) will be captured at nine occasions of assessment: 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post-CTR. The primary focus will be on outcomes up to 1 year.

Captured at 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 3 months, 6 months, 12 months, and 24 months post CTR procedure. Mean opioid use frequency at baseline and 1 week were reported due to highest clinical relevance.
Incision Length in mm
Tidsramme: Recorded at end of procedure (Baseline)

On the day the participant receives their study assigned procedure (USCTR vs. mOCTR), clinical team will record incision length in mm

Recorded at end of procedure (Baseline)
Change in Self-reported Pain as Assessed Using the 11-item Numeric Pain Rating Scale (NPRS)
Tidsramme: Pre-procedure (Baseline) and Immediately post-procedure. Mean immediate post-procedure pain scores were reported.

Using the 11-item Numeric Pain Rating Scale (NPRS), compare the distributions of participant self-reported pain at both pre- and immediately -post CTR procedure between the USCTR and mOCTR groups.

The 11-item NPRS scale is a unidimensional measure of pain intensity. It is a segmented numeric version of the visual analog scale in which participants will select a whole number (0-10 integers) that best reflects the intensity of their pain. The scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. worst possible pain).

Pre-procedure (Baseline) and Immediately post-procedure. Mean immediate post-procedure pain scores were reported.
Change in Self-reported Pain as Assessed Using the Modified 2-item CTS Palmar Pain Scale (4 Items) Over 1 Month Following CTR Procedure
Tidsramme: Captured at 1 week, 2 weeks, 3 weeks, and 1 month post CTR procedure. Mean incisional pain score was reported at 4 weeks and mean incisional pain impact on function score was reported at 3 weeks due to highest clinical relevance.

The Modified 2-item CTS Palmar Pain Scale allows participants to report on their palmar (including pillar pain) and incisional pain and their impact on function separately, with higher scores indicating more pain and functional interference. The amount of palmar and incisional pain was assessed on a scale from 0 (No pain) to 6 (Very severe) and the impact of palmar and incisional pain on function was assessed on a scale from 0 (Not at all) to 5 (Extremely).

Captured at 1 week, 2 weeks, 3 weeks, and 1 month post CTR procedure. Mean incisional pain score was reported at 4 weeks and mean incisional pain impact on function score was reported at 3 weeks due to highest clinical relevance.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Matthew Miller, MD, Walter Reed National Military Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. marts 2021

Primær færdiggørelse (Faktiske)

5. september 2023

Studieafslutning (Faktiske)

6. august 2025

Datoer for studieregistrering

Først indsendt

22. juni 2020

Først indsendt, der opfyldte QC-kriterier

4. august 2020

Først opslået (Faktiske)

7. august 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. oktober 2026

Sidst verificeret

1. september 2025

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner